To confirm that the metabolites contributed to anti-PD-L1 mediated therapy against tumor progression were associated with gut microbial metabolism, we assessed the response of B16 F10 melanoma bearing GF mice receiving anti-PD-L1 and GNV-RNA treatments. The gene discussed is CD274; the disease is neoplasm.